Ortho Evra (norelgestromin/ethinyl
estradiol) Information
FDA has approved changes to the Ortho Evra label to include the results of an additional epidemiology study designed to evaluate the risk of developing serious blood clots, also known as venous thromboembolism (VTE), among women aged 15-44 when using Ortho Evra.
Historical Information
Back
to Top Back to Drug Index
PDF requires the free Adobe Acrobat Reader
Date created: November 10, 2005, updated January 22, 2008
|